Nothing Special   »   [go: up one dir, main page]

BR112017006253A2 - novos compostos - Google Patents

novos compostos

Info

Publication number
BR112017006253A2
BR112017006253A2 BR112017006253A BR112017006253A BR112017006253A2 BR 112017006253 A2 BR112017006253 A2 BR 112017006253A2 BR 112017006253 A BR112017006253 A BR 112017006253A BR 112017006253 A BR112017006253 A BR 112017006253A BR 112017006253 A2 BR112017006253 A2 BR 112017006253A2
Authority
BR
Brazil
Prior art keywords
new compounds
salt
compound
formula
novel compounds
Prior art date
Application number
BR112017006253A
Other languages
English (en)
Inventor
Paul Hancock Ashley
Mary Redmond Joanna
Martin Pritchard John
Howard James Campbell-Crawford Matthew
Andrew Anderson Niall
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of BR112017006253A2 publication Critical patent/BR112017006253A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)

Abstract

resumo "novos compostos" um composto de fórmula (i): (i) em que r representa h ou f, ou um sal do mesmo.
BR112017006253A 2014-09-26 2015-09-22 novos compostos BR112017006253A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1417011.2A GB201417011D0 (en) 2014-09-26 2014-09-26 Novel compounds
PCT/EP2015/071777 WO2016046226A1 (en) 2014-09-26 2015-09-22 Novel compounds

Publications (1)

Publication Number Publication Date
BR112017006253A2 true BR112017006253A2 (pt) 2017-12-12

Family

ID=51901167

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006253A BR112017006253A2 (pt) 2014-09-26 2015-09-22 novos compostos

Country Status (15)

Country Link
US (1) US10000489B2 (pt)
EP (1) EP3197893B1 (pt)
JP (1) JP6665169B2 (pt)
KR (1) KR20170063590A (pt)
CN (1) CN107074849A (pt)
AR (1) AR101995A1 (pt)
AU (1) AU2015320859A1 (pt)
BR (1) BR112017006253A2 (pt)
CA (1) CA2962326A1 (pt)
ES (1) ES2704525T3 (pt)
GB (1) GB201417011D0 (pt)
RU (1) RU2017114346A (pt)
TW (1) TW201629057A (pt)
UY (1) UY36315A (pt)
WO (1) WO2016046226A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
MA46743A (fr) 2016-11-08 2019-09-18 Bristol Myers Squibb Co Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v
JP7128811B2 (ja) 2016-11-08 2022-08-31 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのアゾールアミドおよびアミン
ES2886650T3 (es) 2016-11-08 2021-12-20 Bristol Myers Squibb Co Derivados de indazol como antagonistas de integrina alfaV
SI3538528T1 (sl) * 2016-11-08 2021-03-31 Bristol-Myers Squibb Company Pirol amidi kot alfa v integrin inhibitorji
CA3042710A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
CN110573499B (zh) 2017-02-28 2023-04-21 莫菲克医疗股份有限公司 αvβ6整合蛋白的抑制剂
MA47692A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
CN107823208A (zh) * 2017-10-25 2018-03-23 南京多宝生物科技有限公司 吗啉类化合物在制备治疗和预防肾纤维化药物中的应用
MX2020004455A (es) 2017-11-07 2020-07-24 Bristol Myers Squibb Co Derivados de pirrolopirazina como inhibidores de integrina alfa v.
CN108208177A (zh) * 2017-11-28 2018-06-29 上海交通大学医学院附属新华医院 含丁酸类化合物的组合物及其应用
CN112805001B (zh) 2018-08-29 2024-07-23 莫菲克医疗股份有限公司 抑制αvβ6整联蛋白
WO2020081154A1 (en) 2018-08-29 2020-04-23 Morphic Therapeutic, Inc. INHIBITORS OF ανβ6 INTEGRIN
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
US20210347898A1 (en) * 2018-10-09 2021-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis
CN113490499A (zh) * 2018-12-04 2021-10-08 大日本住友制药肿瘤公司 用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
WO2023225119A1 (en) * 2022-05-18 2023-11-23 Pliant Therapeutics, Inc. Stabilization of integrin inhibitors
WO2024129931A1 (en) 2022-12-14 2024-06-20 Alnylam Pharmaceuticals, Inc. ALPHA-V BETA-6(ανβ6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100397A3 (en) 1997-12-17 2002-10-28 Merck & Co Inc Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation
EP1047425A4 (en) 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
EA200101272A1 (ru) 1999-06-02 2002-06-27 Мерк Энд Ко., Инк. Антагонисты альфа-v интегриновых рецепторов
CA2376077A1 (en) 1999-06-23 2000-12-28 Merck & Co., Inc. Integrin receptor antagonists
JP2003510360A (ja) * 1999-10-04 2003-03-18 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
BR0015384A (pt) 1999-11-08 2002-10-08 Merck & Co Inc Processo para a preparação de um composto, e, composto
AU2001269876A1 (en) 2000-06-15 2001-12-24 Mark Laurence Boys Heteroarylalkanoic acids as integrin receptor antagonists
ATE353219T1 (de) 2000-07-26 2007-02-15 Merck & Co Inc Alpha v integrin-rezeptor-antagonisten
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
CA2432504A1 (en) 2001-01-03 2002-07-11 Merck & Co., Inc. Methods and compositions for treating periodontal disease
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
MXPA05006727A (es) 2002-12-20 2005-09-08 Pharmacia Corp Acidos heteroarilalcanoicos como antagonistas de receptor de integrina.
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
PT2139882E (pt) 2007-03-23 2014-01-30 Amgen Inc Derivados de quinolina ou quinoxalina 3-substituídos e sua utilização como inibidores de fosfatidilinositol 3-cinase (pi3k)
EP2211615A4 (en) 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
KR102647026B1 (ko) 2015-02-19 2024-03-12 사이플루어 라이프 사이언시즈, 인크 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도
JP2018515424A (ja) 2015-03-10 2018-06-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗アルファｖベータ１インテグリン阻害剤及び使用方法
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
TW201629057A (zh) 2016-08-16
EP3197893B1 (en) 2018-10-24
AR101995A1 (es) 2017-01-25
CN107074849A (zh) 2017-08-18
CA2962326A1 (en) 2016-03-31
US20170298063A1 (en) 2017-10-19
JP2017528503A (ja) 2017-09-28
GB201417011D0 (en) 2014-11-12
JP6665169B2 (ja) 2020-03-13
AU2015320859A1 (en) 2017-03-09
US10000489B2 (en) 2018-06-19
EP3197893A1 (en) 2017-08-02
UY36315A (es) 2016-04-29
RU2017114346A (ru) 2018-11-02
WO2016046226A1 (en) 2016-03-31
KR20170063590A (ko) 2017-06-08
ES2704525T3 (es) 2019-03-18

Similar Documents

Publication Publication Date Title
BR112017006253A2 (pt) novos compostos
CL2017000705A1 (es) Nuevos compuestos
PH12020500673A1 (en) Compounds
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
BR112017002827A2 (pt) derivado de quinolina altamente puro e método para produção do mesmo
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
BR112017006240A2 (pt) novos compostos
MA40301B1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
EA201692219A1 (ru) Способы получения противовирусных соединений
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
RS54730B1 (sr) Inhibitori beta sekretaze
CR20170315A (es) Inhibridores bace 1 selectivos
MA40302B1 (fr) Dérivés de carbazole
AR095523A1 (es) Derivados piridin-4-ilo
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
AR101036A1 (es) Amidas de benzoxazinona como reguladores del receptor mineralocorticoide
BR112018008006A2 (pt) composto de piranodipiridina
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
BR112018012325A2 (pt) métodos para a preparação de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina substituída
BR112016027455A2 (pt) moduladores ppar
EA201892449A1 (ru) Конденсированные гетероциклические соединения
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]